RightFit
RecruitingPhase not listed

COPD Exacerbation Follow Up

A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether an AI tool called Viz COPD helps patients get follow-up care from lung specialists and improves their health after a COPD flare-up. It is for adults age 40 or older with COPD, a long-term lung disease, who come to the emergency department with a moderate or severe flare-up.

The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Age 40 or older when arriving at the emergency department.
  • Have a COPD diagnosis and come to the emergency department for a moderate or severe flare-up.
  • A moderate flare-up needs steroid medicine by mouth, shot, or IV (into a vein), antibiotics, or both.
  • A severe flare-up requires a hospital stay, more than 24 hours of observation in emergency or urgent care, or results in death.
  • Use a long-acting inhaler treatment with two or three medicine types: LABA and LAMA (medicines that open airways), or either or both with ICS (an inhaled steroid).

Who can't join

  • Use only one type of inhaled medicine to open the airways.
  • Leave the hospital against medical advice or die during the hospital stay.
  • Have a tracheostomy, an opening made in the neck to help with breathing.
  • Have advanced cancer.
  • Have had a lung transplant.
  • Are sent to hospice care, which focuses on comfort near the end of life.
  • Are moved to another hospital.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Patients aged 40 years or older at the time of arrival to the emergency department. * Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation. * A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. * A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \>24 hours in emergency department/urgent care facility or resulting in death. * Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers. Exclusion Criteria: * Patients on bronchodilator inhaler monotherapy. * Patients leaving against medical advice or expiring during hospitalization. * Patients with tracheostomy. * Patients with advanced cancer. * Patients who have received a lung transplant. * Discharge to hospice care. * Transfer to another hospital.

Study sites (5)

IL

NJ

PA

VA

WI